The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent increase from 2023, according to a Globe analysis of insurance claims data.

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

Pharmacy leaders have issued a fresh warning over the online sale of weight-loss jabs insisting there is still a risk to patient safety. The National Pharmacy Association (NPA) has called for tougher rules in a letter to regulators,

Pharmacy leaders warn against the online sale of weight-loss jabs, highlighting risks to patient safety and improper prescriptions for individuals with low body weight or prior eating disorders. The National Pharmacy Association (NPA) calls for tighter rules and urges a mandatory 20-minute consultation instead of relying on online questionnaires to access drugs like Wegovy and Mounjaro.

The NPA said it was also aware of people being wrongly prescribed the drugs who have previously had eating disorders, or whose body weight is already low. The body, which represen